Inhibikase Therapeutics, Inc. - IKT

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Feb 17, 2026 SCHEDULE 13G/A Fairmount Funds Management LLC 9.9% 12,461,101 View
Feb 17, 2026 SCHEDULE 13G/A Fairmount Healthcare Fund II L.P. 9.9% 12,461,101 View
Feb 17, 2026 SCHEDULE 13G/A Peter Harwin 9.9% 12,461,101 View
Feb 17, 2026 SCHEDULE 13G/A Tomas Kiselak 9.9% 12,461,101 View
Feb 17, 2026 SCHEDULE 13G/A ADAR1 Capital Management, LLC 9.9% 12,523,371 View
Feb 17, 2026 SCHEDULE 13G/A ADAR1 Capital Management GP, LLC 9.9% 12,692,387 View
Feb 17, 2026 SCHEDULE 13G/A Daniel Schneeberger 9.9% 12,523,371 View
Feb 17, 2026 SCHEDULE 13G/A Perceptive Advisors LLC 9.99% 12,816,643 View
Feb 17, 2026 SCHEDULE 13G/A Joseph Edelman 9.99% 12,816,643 View
Feb 17, 2026 SCHEDULE 13G/A Perceptive Life Sciences Master Fund, Ltd. 9.99% 12,816,643 View
Feb 13, 2026 SCHEDULE 13G/A Sands Capital Life Sciences Pulse Fund II, L.P. 10.8% 13,018,965 View
Feb 13, 2026 SCHEDULE 13G/A Sands Capital Alternatives, LLC 10.8% 13,018,965 View
Feb 13, 2026 SCHEDULE 13G/A SANDS FRANK M. 10.8% 13,018,965 View
Feb 13, 2026 SCHEDULE 13G/A Nantahala Capital Management, LLC 5.68% 7,037,916 View
Feb 13, 2026 SCHEDULE 13G/A Wilmot B. Harkey 5.68% 7,037,916 View
Feb 13, 2026 SCHEDULE 13G/A Daniel Mack 5.68% 7,037,916 View
Dec 31, 2025 SCHEDULE 13G Trails Edge Capital Partners, LP 5.1% 6,145,198 View
Dec 31, 2025 SCHEDULE 13G Trails Edge Biotechnology Master Fund, LP 5.1% 6,145,198 View
Dec 31, 2025 SCHEDULE 13G Ortav Yehudai 5.1% 6,145,198 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.